Personalis (NASDAQ:PSNL) Given New $11.00 Price Target at HC Wainwright

Personalis (NASDAQ:PSNL) had its price objective hoisted by stock analysts at HC Wainwright from $9.00 to $11.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target would suggest a potential upside of 109.13% from the company’s previous close.

Separately, Needham & Company LLC reissued a “buy” rating and issued a $7.25 target price on shares of Personalis in a report on Friday.

Personalis Stock Performance

Shares of PSNL opened at $5.26 on Friday. Personalis has a 1 year low of $1.12 and a 1 year high of $7.20. The stock has a market capitalization of $371.61 million, a PE ratio of -3.13 and a beta of 1.88. The stock has a 50-day simple moving average of $4.35 and a 200-day simple moving average of $3.85.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.31). Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. The firm had revenue of $25.71 million during the quarter, compared to analysts’ expectations of $20.67 million. During the same quarter in the prior year, the firm earned ($0.51) EPS. Analysts predict that Personalis will post -1.41 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. ARK Investment Management LLC raised its stake in Personalis by 11.4% during the 3rd quarter. ARK Investment Management LLC now owns 7,085,523 shares of the company’s stock worth $38,120,000 after acquiring an additional 723,637 shares in the last quarter. Walleye Capital LLC purchased a new position in shares of Personalis during the third quarter worth about $897,000. Jane Street Group LLC increased its position in shares of Personalis by 154.3% during the third quarter. Jane Street Group LLC now owns 164,281 shares of the company’s stock worth $884,000 after purchasing an additional 99,671 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Personalis by 20.0% in the 3rd quarter. Geode Capital Management LLC now owns 498,470 shares of the company’s stock valued at $2,683,000 after purchasing an additional 83,068 shares during the last quarter. Finally, Centiva Capital LP purchased a new stake in shares of Personalis in the 3rd quarter valued at about $380,000. Institutional investors and hedge funds own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.